The 2023 Biosimilars Market Report

Our Third Edition Will Be Ready for Publication in Dec 2022/Jan 2023

So much changes from year to year in the biosimilar marketplace, and we recognize the value only the latest information will provide. The highly sought 2021 edition listed 29 biosimilars approved in the US for 9 reference products (but a significant number are as yet unmarketed). As of late February 2022, this number is only slightly higher (32 approved for 11 reference products), and the number of marketed biosimilars has only changed with the addition of insulin glargine. However, the first two interchangeable biosimilars have officially been designated by the FDA, and much has happened outside of drug approvals that has affected biosimilar policy, pipeline, and payer decision making. The US Supreme Court has ruled on the validity of the ACA and as a result, the BPCIA. Payers are beginning to devise their strategies ahead of huge adalimumab launches in 2023. And future biosimilar interest in specific biologic reference products is coalescing around revenue expectations, perceived opportunity, and a better sense of who will continue to play in this market space.

The updated 2023 edition of the publication Where the US Biosimilars Market Is Heading and When It Might Get There will continue a tradition of being a vital, independent resource for those managing drug benefits, designing medical and pharmacy coverage policies, prescribing biologic medications, and the manufacturers of biosimilars and biologics alike.

The 2023 edition will update the biosimilar story–past, present, and future–of the industry in the US.

Check back soon for our newest listing of features for 2023!

  • Note: This publication is supplied for personal use only. We are happy to provide discounted pricing for multiple copies.

The table of contents of the 2021 Edition (no longer available) of Where the US Biosimilars Market Is Heading and When It Might Get There included:

Section 1: Access and Competition

  • Setting the Stage
  • How Reference Manufacturers Hinder Biosimliar Competition and Access
  • How Biosimilar Manufacturers Hinder Access to Their Products
  • Federal Factors That Negatively Influence Biosimilar Competition
  • Payers Don’t Specifically Optimize Biosimilar Uptake
  • Factors Working in Favor of Improving Biosimilar Access and Competition

Section 2: Marketplace Insights

  • The G-CSF US Marketplace
  • The Trastuzumab US Marketplace
  • The Infliximab US Marketplace
  • The Adalimumab US Marketplace
  • The Insulin Transition to Biosimilars and the
    Biosimilars Pipeline

Section 3: Looking Ahead

  • Forcing Factors and the Future of Biosimilars in the US
  • State of Texas v. USA and the Potential Implications for Biosimilars
  • Long-Term Sustainability: With Fewer Blockbusters, Will There Be Interest in Biosimilars for Lower-Revenue Products?
  • A Summing Up: Final Thoughts on 2021, 2023, and Beyond

Readers of Where the US Biosimilars Market Is Heading and When It Might Get There will gain comprehensive business perspective on the biosimilar industry’s past, present, and future.

Showing the single result